Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2
Nature
.
2022 Apr;604(7905):E14.
doi: 10.1038/s41586-022-04653-w.
Authors
Lucy G Thorne
#
1
,
Mehdi Bouhaddou
#
2
3
4
5
,
Ann-Kathrin Reuschl
#
1
,
Lorena Zuliani-Alvarez
#
2
3
4
5
,
Ben Polacco
2
3
4
5
,
Adrian Pelin
2
3
4
5
,
Jyoti Batra
2
3
4
5
,
Matthew V X Whelan
1
,
Myra Hosmillo
6
,
Andrea Fossati
2
3
4
5
,
Roberta Ragazzini
7
,
Irwin Jungreis
8
9
,
Manisha Ummadi
2
3
4
5
,
Ajda Rojc
2
3
4
5
,
Jane Turner
1
,
Marie L Bischof
1
,
Kirsten Obernier
2
3
4
5
,
Hannes Braberg
2
3
4
5
,
Margaret Soucheray
2
3
4
5
,
Alicia Richards
2
3
4
5
,
Kuei-Ho Chen
2
3
4
5
,
Bhavya Harjai
2
3
4
5
,
Danish Memon
10
,
Joseph Hiatt
2
3
4
5
,
Romel Rosales
11
12
,
Briana L McGovern
11
12
,
Aminu Jahun
6
,
Jacqueline M Fabius
2
3
4
5
,
Kris White
11
12
,
Ian G Goodfellow
6
,
Yasu Takeuchi
1
,
Paola Bonfanti
7
,
Kevan Shokat
2
3
4
5
13
,
Natalia Jura
2
3
5
14
15
,
Klim Verba
2
3
5
,
Mahdad Noursadeghi
1
,
Pedro Beltrao
2
10
,
Manolis Kellis
8
9
,
Danielle L Swaney
2
3
4
5
,
Adolfo García-Sastre
11
12
16
17
18
,
Clare Jolly
19
,
Greg J Towers
20
,
Nevan J Krogan
21
22
23
24
Affiliations
1
Division of Infection and Immunity, University College London, London, UK.
2
QBI Coronavirus Research Group (QCRG), University of California San Francisco, San Francisco, CA, USA.
3
Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.
4
J. David Gladstone Institutes, San Francisco, CA, USA.
5
Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
6
Division of Virology, Department of Pathology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
7
Epithelial Stem Cell Biology and Regenerative Medicine Laboratory, The Francis Crick Institute, London, UK.
8
MIT Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA, USA.
9
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
10
European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
11
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
12
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
13
Howard Hughes Medical Institute, San Francisco, CA, USA.
14
Division of Advanced Therapies, National Institute for Biological Standards and Control, South Mimms, UK.
15
Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
16
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
17
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
18
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
19
Division of Infection and Immunity, University College London, London, UK. c.jolly@ucl.ac.uk.
20
Division of Infection and Immunity, University College London, London, UK. g.towers@ucl.ac.uk.
21
QBI Coronavirus Research Group (QCRG), University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
22
Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
23
J. David Gladstone Institutes, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
24
Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
#
Contributed equally.
PMID:
35332335
PMCID:
PMC8944406
DOI:
10.1038/s41586-022-04653-w
No abstract available
Publication types
Published Erratum
Grants and funding
T32 GM141323/GM/NIGMS NIH HHS/United States